- Home
- VANI vs OTLK Comparison
VANI vs OTLK Comparison
Compare VANI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- OTLK
- Stock Information
- Founded
- VANI 1998
- OTLK 2010
- Country
- VANI United States
- OTLK United States
- Employees
- VANI N/A
- OTLK N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VANI Health Care
- OTLK Health Care
- Exchange
- VANI Nasdaq
- OTLK Nasdaq
- Market Cap
- VANI 69.3M
- OTLK 56.3M
- IPO Year
- VANI 2014
- OTLK 2016
- Fundamental
- Price
- VANI $1.15
- OTLK $1.56
- Analyst Decision
- VANI Strong Buy
- OTLK Strong Buy
- Analyst Count
- VANI 1
- OTLK 5
- Target Price
- VANI $3.00
- OTLK $12.00
- AVG Volume (30 Days)
- VANI 83.2K
- OTLK 650.8K
- Earning Date
- VANI 03-25-2025
- OTLK 02-14-2025
- Dividend Yield
- VANI N/A
- OTLK N/A
- EPS Growth
- VANI N/A
- OTLK N/A
- EPS
- VANI N/A
- OTLK N/A
- Revenue
- VANI N/A
- OTLK N/A
- Revenue This Year
- VANI N/A
- OTLK N/A
- Revenue Next Year
- VANI N/A
- OTLK $396.84
- P/E Ratio
- VANI N/A
- OTLK N/A
- Revenue Growth
- VANI N/A
- OTLK N/A
- 52 Week Low
- VANI $1.01
- OTLK $0.87
- 52 Week High
- VANI $7.80
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- VANI 43.02
- OTLK 34.22
- Support Level
- VANI $1.12
- OTLK $1.58
- Resistance Level
- VANI $1.19
- OTLK $1.99
- Average True Range (ATR)
- VANI 0.03
- OTLK 0.15
- MACD
- VANI 0.00
- OTLK -0.00
- Stochastic Oscillator
- VANI 42.86
- OTLK 6.52
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.